Leuzek (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug stops the signaling pathways that promote uncontrolled cell division and survival, leading to cancer cell death.

The dose of Leuzek is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact regimen provided by their healthcare professional.

Safety of imatinib during pregnancy or lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Leuzek.

To order Leuzek, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leuzek (imatinib) belongs to the class of tyrosine kinase inhibitors and is often considered first‑line therapy for chronic myeloid leukemia and gastrointestinal stromal tumor. Compared with newer agents, it has a well‑characterized safety profile and extensive clinical experience, though individual response and tolerability may vary.

Leuzek should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Leuzek is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Dosing times and any food restrictions are determined by the prescriber.

Serious risks include severe neutropenia, hepatotoxicity, and cardiac failure. Patients should be monitored regularly for blood count changes, liver enzyme elevations, and signs of heart dysfunction, and any concerning symptoms should be reported promptly to a clinician.

Leuzek is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that strongly interact with imatinib.